Clinical trial
A Phase 2 Multicenter Platform Trial of Targeted Therapies for Treatment of Adult Subjects With Moderate to Severe Psoriasis
NCT07933536 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Multicenter Platform Trial of Targeted Therapies for Treatment of Adult Subjects With Moderate to Severe Psoriasis
- Lead sponsor
- AbbVie
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 3, 2026
- Completion date
- December 31, 2028
- Enrollment
- 105 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe psoriasis
Arms
As registered; 2 arms.
-
Risankizumab and ABBV-295 Combination Therapy
Participants will receive risankizumab in combinations with ABBV-295 for up to 52 weeks.
-
Risankizumab and ABBV-295 Matching Placebo
Participants will receive risankizumab with ABBV-295 matching placebo for up to 52 weeks.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Percentage of Participants Achieving at least a 90% reduction from Baseline in Psoriasis Area and Severity Index (PASI 90)
PASI is a measure of psoriatic disease severity taking into account the overall severity of erythema, induration and scaling, and the extent of affected area in each of four anatomical regions (head, trunk, upper extremities, and lower extremities). PASI scores range from 0 (no psoriasis) to 72 (severe disease over the entire body surface). Higher scores indicate worse disease severity. PASI 90 indicates at least 90% improvement from baseline.
-
Number of Participants with Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Lead sponsor's other trials
AbbVie, most recent start first.
+1,194 more trials See the organization page
Similar trials
Same condition (Psoriasis) and phase, most recent start first.
+253 more trials See the condition page